Phase 2 trial of TAS-102 plus bevacizumab in patients with advanced/recurrent colorectal cancer who had previously received on oxaliplatin, irinotecan and fluoropyrimidine
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2641267
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 15-20 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. 1 cycle is 28days.
Primary outcome(s): Disease control rate
Study Design: Single arm Non-randomized
创建时间：
2016-03-15
